Close Menu

NEW YORK (GenomeWeb) – Curetis said today that its full-year 2018 revenues grew 17 percent year over year.

For the 12 months ended Dec. 31, 2018, the molecular diagnostics development firm reported revenues of €1.4 million ($1.6 million), up from €1.2 million in 2017.

The company said its R&D costs grew 43 percent year over year to €10.6 million from €7.4 million while its administrative costs were up 8 percent to €4.1 million from €3.8 million, and its distribution costs rose 12 percent to €8.2 million from €7.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.

Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.

NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.

In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.